A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Brain Metastases
Interventions: DRUG: Afatinib|DRUG: T-DM1
Sponsor: xuexin he